6.5 Golimumab, 50 mg 0.5 mL injection, 1x 0.5 mL, syringe Simponi®; Infliximab, 100 mg injection, 1x 100 mg vial, Remicade®; Ustekinumab 45 mg 0.5 ml injection, 1x 0.5 ml vial, - Janssen - Document - PDFSEARCH.IO

First Page		Document Content
Date: 2015-04-22 23:39:46 Pharmaceutical sciences Immunosuppressants Monoclonal antibodies Ustekinumab Infliximab Golimumab Clinical trial Biologic Psoriasis Centocor Pharmacology Medicine		6.5 Golimumab, 50 mg/0.5 mL injection, 1x 0.5 mL, syringe Simponi®; Infliximab, 100 mg injection, 1x 100 mg vial, Remicade®; Ustekinumab 45 mg/0.5 ml injection, 1x 0.5 ml vial, Add to Reading List Source URL: www.pbs.gov.au Download Document from Source Website File Size: 176,09 KB Share Document on Facebook

	CONTACT: Media: Charlene McGrady, extMDS Pharma Services Scientist to Discuss Development of Biosimilar Monoclonal Antibodies at EGA Symposium DocID: 1vhgc - View Document
	ABIRISK ABIRISK Project Officially Started A growing number of medicines are based on biological molecules such as proteins and monoclonal antibodies. These novel drugs have resulted in new, more effective treatments for DocID: 1v3WA - View Document
	Celartia Protocols Hybridoma Cell culture with Petaka-HOT (High Oxygen Turnover, orange port) Production of Monoclonal Antibodies Petaka-HOT allows culturing non adherent DocID: 1uTpm - View Document
	INTERNSHIP PROPOSAL Institute and Group: IBS group HIV and persistent human viruses Supervisor: Pascal Poignard Email: Research project title: Human monoclonal antibodies: a new therapeutic strategy DocID: 1uPEI - View Document
	Visterra Acquires Exclusive Patent License for Monoclonal Antibodies against Dengue Virus from MIT – Expands Company’s Therapeutic Pipeline for Infectious Diseases – Cambridge, MA – December 2, 2013 – Visterra, DocID: 1ujGa - View Document